The histone methyltransferase MLL1 complex inhibits expression of fetal hemoglobin
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.110863 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Yufen Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Histone-Lysine N-Methyltransferase, Fetal Hemoglobin, Myeloid-Lymphoid Leukemia Protein, Proto-Oncogene Proteins. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CCR NIH HHS, NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Increasing fetal-type hemoglobin expression in adult erythroid cells holds promise in the treatment of sickle cell disease (SCD) and β-thalassemia. We have identified the MLL1 complex as a critical regulator of fetal and embryonic hemoglobin repression. Knockdowns of MEN1 and KMT2A, encoding essential components of the complex, caused a significant downregulation of BCL11A expression and a substantial increase in γ- and ε-globin mRNA levels in HUDEP-2 cells. Significant binding of MEN1 and KMT2A was readily detected at the promoter and a critical enhancer of BCL11A in HUDEP-2 cells, suggesting that BCL11A is a direct transcriptional target of the MLL1 complex. Consistent with these results, MEN1 or KMT2A knockdown in normal human CD34+ hematopoietic stem and progenitor cells induced to undergo erythroid differentiation also significantly decreased their BCL11A expression and increased their γ- and ε-globin expression and the production of F cells in the culture. Treatment of these cells with MENIN inhibitors yielded similar results and promoted erythroid differentiation with minimal effects on their growth. Moreover, treatment of CD34+ hematopoietic stem and progenitor cells from SCD patients with MENIN inhibitors substantially increased γ-globin expression in their erythroid progenies. These findings underscore a critical role of the MLL1 complex in regulating fetal and embryonic hemoglobin expression and suggest that MENIN inhibitors could offer a promising therapeutic approach for SCD and β-thalassemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
- Molecular and Clinical Hematology Branch, NHLBI, NIH, Bethesda, Maryland, USA.
- Center for Advanced Preclinical Research, Leidos Biomedical Research Inc, Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
- Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA. Electronic address: yang.du@usuhs.edu.
Förderung
- CCR NIH HHS
- NCI NIH HHS
- National Institutes of Health
- National Heart Lung and Blood Institute Division of Intramural Research
- Uniformed Services University of the Health Sciences
- National Heart, Lung, and Blood Institute
- U.S. Department of Health and Human Services
- Defense Health Agency Consortium
Zitieren
APA
Han, Y., Gudmundsdottir, B., Gudmundsson, K. O., Roy, K. R., Tisdale, J., & Du, Y. (2025). The histone methyltransferase MLL1 complex inhibits expression of fetal hemoglobin. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110863
Vancouver
Han Y, Gudmundsdottir B, Gudmundsson KO, Roy KR, Tisdale J, Du Y. The histone methyltransferase MLL1 complex inhibits expression of fetal hemoglobin. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.110863
BibTeX
@article{Han2025,
author = {Han, Yufen and Gudmundsdottir, Bjorg and Gudmundsson, Kristbjorn O and Roy, Kartik R and Tisdale, John and Du, Yang},
title = {The histone methyltransferase MLL1 complex inhibits expression of fetal hemoglobin},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.110863}
}
EUVIMED